Cambrex Corporation (N:CBM)

Nov 14, 2019 07:30 am ET
Cambrex Wins Third API Development Award at CPhI Worldwide
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, has won the ‘Excellence in Pharma: API Development’ category at the annual CPhI...
Oct 24, 2019 06:40 am ET
Cambrex Releases Selected Preliminary Third Quarter 2019 Financial Results
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that in connection with the debt portion of the financing for the...
Sep 25, 2019 05:17 pm ET
Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Highlands, Cambrex, Two River, and Carbon Black on behalf of Stockholders and Encourages Investors to Contact
Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Highlands Bankshares, Inc. (Other OTC: HLND), Cambrex Corporation (NYSE: CBM), Two River Bancorp (NASDAQ: TRCB), and Carbon...
Sep 23, 2019 01:28 pm ET
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – NCI, CBM, VSI, WAIR
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Navigant Consulting, Inc. (NYSE: NCI)The investigation concerns whether Navigant Consulting and its board of directors violated the federal...
Sep 23, 2019 06:40 am ET
Cambrex Corporation Announces Expiration of “Go Shop” Period Under Merger Agreement
Cambrex Corporation (NYSE: CBM) (the “Company” or “Cambrex”) today announced the expiration, as of 12:01 a.m., Eastern Time, on September 22, 2019, of the 45-day “go shop” period under the previously announced Agreement and Plan of Merger, dated as...
Sep 17, 2019 10:44 am ET
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – CBM, WAIR, AVDR, PSDO
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cambrex Corporation (NYSE: CBM)The investigation concerns whether Cambrex and its board of directors violated the federal securities laws and/or...
Sep 11, 2019 08:15 pm ET
Bragar Eagel & Squire, P.C. Announces that it is Investigating the Boards of Directors of Cambrex, Presidio, Old Line Bancorp, and Milacron Holdings on behalf of Stockholders and Encourages Investors
Bragar Eagel & Squire, P.C. announces to investors that it is investigating potential claims on behalf of stockholders of Cambrex Corp. (NYSE: CBM), Presidio, Inc. (NASDAQ: PSDO), Old Line Bancshares (NASDAQ: OLBK), and Milacron Holdings Corp....
Sep 11, 2019 01:18 pm ET
Shareholder Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – CBM, WAIR, SRCI, MCRN
Halper Sadeh LLP, a global investor rights law firm, continues to investigate the following companies: Cambrex Corporation (NYSE: CBM)The investigation concerns whether Cambrex and its board of directors violated the federal securities laws and/or...
Sep 10, 2019 10:39 am ET
MAMS, CBM, ABDC, and NCI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: MAM Software Group, Inc. (NASDAQ GS: MAMS) regarding possible breaches of fiduciary duties and other violations of law related to MAM Software’s agreement to be acquired by Kerridge...
Sep 06, 2019 05:50 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds NRCG, NCI, CBM, and TRCB Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway,...
Sep 04, 2019 09:39 am ET
PVTL, CBM, VSI and AVDR SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Pivotal Software (NYSE: PVTL) regarding possible breaches of fiduciary duties and other violations of law related to Pivotal’s agreement to be acquired by VMware, Inc. (NYSE: VMW)....
Sep 03, 2019 09:00 am ET
Merger Investigation Alert: Halper Sadeh LLP Continues to Investigate Whether the Sale of These Companies is Fair to Shareholders – MCRN, TYPE, GHDX, CBM
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Milacron Holdings Corp. (NYSE: MCRN)The investigation concerns whether Milacron and its board of directors violated the federal securities...
Aug 19, 2019 12:38 pm ET
TRCB, VSI, CBM, and TRK SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Two River Bancorp (NASDAQ GM: TRCB) regarding possible breaches of fiduciary duties and other violations of law related to Two River’s agreement to be acquired by OceanFirst Financial...
Aug 16, 2019 04:25 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Reminds CBM, VSI and NCI Shareholders About Its Ongoing Investigations
If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact: Joshua Rubin, Esq. WeissLaw LLP 1500 Broadway, 16th...
Aug 14, 2019 11:14 am ET
Shareholder Investigation Alert: Halper Sadeh LLP is Investigating Whether The Sale of These Companies is Fair to Shareholders – CBM, GCI, WAIR, ACIA
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Cambrex Corporation (NYSE: CBM)The investigation concerns whether Cambrex and its board of directors violated the federal securities laws...
Aug 13, 2019 05:52 pm ET
CAMBREX INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Cambrex Corporation - CBM
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Cambrex Corporation (NYSE: CBM) to an affiliate of the Permira funds. Under the terms of the proposed transaction, shareholders of Cambrex will receive only $60.00 in cash for each share of Cambrex that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company.
Aug 13, 2019 12:32 pm ET
TRCB, AVDR, CBM, and NCI SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Two River Bancorp (NASDAQ GM: TRCB) regarding possible breaches of fiduciary duties and other violations of law related to Two River’s agreement to be acquired by OceanFirst Financial...
Aug 13, 2019 11:01 am ET
MERGER ALERT –NCI, AVDR, and CBM: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Navigant Consulting, Inc. (NYSE: NCI)...
Aug 09, 2019 08:00 pm ET
URGENT: Monteverde & Associates PC is Investigating the Following Transaction
NEW YORK, Aug. 9, 2019 /PRNewswire/ -- Juan Monteverde, founder and managing partner at Monteverde & Associates PC, a national securities firm headquartered at the Empire State Building in New York City, is investigating: ...
Aug 09, 2019 11:17 am ET
Shareholder Investigation Alert: Halper Sadeh LLP is Investigating Whether The Sale of These Companies is Fair to Shareholders – GCI, CBM, CVRS, VSI
Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Gannett Co., Inc. (NYSE: GCI)The investigation concerns whether Gannett and its board of directors violated the federal securities laws...
Aug 09, 2019 10:00 am ET
GCI, CBM, VSI and CVRS SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Buyouts
Rigrodsky & Long, P.A. announces that it is investigating: Gannett Co., Inc. (NYSE: GCI) regarding possible breaches of fiduciary duties and other violations of law related to Gannett’s agreement to merge with New Media Investment Group Inc....
Aug 08, 2019 04:54 pm ET
SHAREHOLDER ALERT: WeissLaw LLP Investigates Cambrex Corp.
NEW YORK, Aug. 8, 2019 /PRNewswire/ -- WeissLaw LLP is conducting an active investigation of possible breaches of fiduciary duty and other violations of law by the Board of Directors of Cambrex Corp. ("Cambrex" or the "Company") (NYSE: CBM) in connection with the proposed acquisition of the Company by private equity firm Permira Funds ("Permira").  Under the terms of the acquisition agreement, Cambrex shareholders will receive $60.00 per CBM share....
Aug 08, 2019 10:29 am ET
MERGER ALERT – NCI, GCI, and CBM: Levi & Korsinsky, LLP Reminds Investors of Investigations Concerning the Sale of these Companies
The following statement is being issued by Levi & Korsinsky, LLP: Levi & Korsinsky, LLP announces that investigations have commenced on behalf of shareholders of the following publicly-traded companies. Navigant Consulting, Inc. (NYSE: NCI)...
Aug 07, 2019 06:09 pm ET
Bragar Eagel & Squire, P.C. is Investigating the Board of Directors of Cambrex Corporation (NYSE: CBM) on Behalf of Cambrex Shareholders and Encourages Cambrex Investors to Contact the Firm
NEW YORK, Aug. 7, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Cambrex Corporation (NYSE: CBM) on behalf of Cambrex shareholders concerning the proposed merger with an affiliate of the private equity firm Permira Funds....
Aug 07, 2019 04:02 pm ET
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Regarding Whether the Sale of Cambrex Corporation to the Permira funds is Fair to Shareholders
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Cambrex Corporation (“Cambrex” or the “Company”) (NYSE: CBM) stock prior to August 7, 2019. You are hereby notified that Levi & Korsinsky,...
Aug 07, 2019 02:10 pm ET
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Cambrex Corporation
NEW YORK, Aug. 7, 2019 /PRNewswire/ -- Rowley Law PLLC is investigating potential claims against Cambrex Corporation (NYSE: CBM) and its board of directors for breach of fiduciary duty concerning the proposed acquisition of the company by an affiliate of the Permira funds. Stockholders will receive $60.00 for each share of Cambrex Corporation stock that they hold. The transaction is valued at approximately $2.4 billion (including debt) and is expected to close in the fourth quarter of 2019....
Aug 07, 2019 12:55 pm ET
Cambrex Cancels Second Quarter Earnings Conference Call and Will Not Update Financial Guidance
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it will not hold a second quarter 2019 earnings conference...
Aug 07, 2019 11:19 am ET
Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Cambrex Corporation has obtained a Fair Price in its sale to Permira Funds
MILWAUKEE, Aug. 7, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Cambrex (NYSE: CBM) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Cambrex to Permira. ...
Aug 07, 2019 10:02 am ET
Cambrex Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Cambrex Corporation is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – CBM
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Cambrex Corporation (NYSE: CBM) to an affiliate of the Permira funds (“Permira”) for $60.00 per share is fair to Cambrex shareholders. On behalf of Cambrex...
Aug 07, 2019 07:49 am ET
Cambrex (CBM) Alert: Johnson Fistel Investigates Proposed Sale of Cambrex Corporation; Is $60 a Fair Price?
SAN DIEGO, Aug. 7, 2019 /PRNewswire/ -- Shareholder rights law firm Johnson Fistel, LLP has launched an investigation into whether the board members of Cambrex Corporation (NYSE: CBM) ("Cambrex") breached their fiduciary duties in connection with the proposed sale of the Company to private equity firm Permira....
Aug 07, 2019 06:30 am ET
Cambrex to be Acquired by the Permira Funds for $60.00 per Share in Cash
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, announced today that it has signed a definitive agreement to be acquired by an...
Aug 06, 2019 10:10 am ET
Cambrex to Announce Second Quarter 2019 Financial Results on August 9, 2019
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that second quarter 2019 financial results will be released on...
Jul 30, 2019 08:00 am ET
Cambrex to Double Size of Edinburgh Solid Form Screening Facility
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it is expanding its solid form screening and crystallization...
Jun 26, 2019 08:00 am ET
Cambrex Strengthens Leadership Team to Support Integrated Small Molecule End-to-End Service Offering
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced three senior appointments to further support the company’s strategy...
Jun 25, 2019 08:00 am ET
Cambrex Appoints Dottie Donnelly-Brienza as Senior Vice President and Chief Human Resources Officer
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that Dottie Donnelly-Brienza has been appointed Senior Vice...
Jun 04, 2019 08:00 am ET
Cambrex Completes New Process and Analytical Development Facility at its Karlskoga, Sweden Manufacturing Site
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed a new 600 m2 facility at its site in...
May 29, 2019 10:00 am ET
Cambrex to Present at Upcoming Investor Conferences in June
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that company management will present at the following investor...
May 02, 2019 06:40 am ET
Cambrex Reports First Quarter 2019 Financial Results
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, reports results for the first quarter ended March 31, 2019. First Quarter 2019...
Apr 30, 2019 10:45 am ET
Cambrex to Announce First Quarter 2019 Financial Results on May 2, 2019
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that first quarter 2019 financial results will be released on...
Apr 23, 2019 08:00 am ET
Cambrex Completes New Quality Control Laboratory for Generic API Development in Milan
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had opened a new 120m2 quality control (QC) laboratory at...
Apr 10, 2019 08:00 am ET
Cambrex Completes Highly Potent API Manufacturing Facility at Charles City, IA
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it had completed the construction of a $24 million highly...
Mar 29, 2019 07:25 am ET
Factors of Influence in 2019, Key Indicators and Opportunity within Nutanix, Steel Dynamics, Audentes Therapeutics, Comfort Systems, LHC Group, and Cambrex — New Research Emphasizes Economic Growth
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Nutanix Inc. (NASDAQ:NTNX), Steel Dynamics, Inc. (NASDAQ:STLD),...
Mar 26, 2019 08:00 am ET
Cambrex Doubles cGMP Liquid Filling Capacity at its Mirabel, Québec Facility
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced it will double the liquid packaging capacity and weekly output at...
Mar 14, 2019 08:00 am ET
Cambrex Completes Expansion and Manufacturing Capability Upgrades in Milan
Cambrex Corporation (NYSE: CBM), the leading small molecule company providing drug substance, drug product and analytical services across the entire drug lifecycle, today announced that it has completed the expansion of a new 150m2 research and...
Feb 13, 2019 06:40 am ET
Cambrex Reports Fourth Quarter and Full Year 2018 Financial Results
Cambrex Corporation (NYSE: CBM), a leading provider of development, manufacturing, testing and technology services for small molecules, reports results for the fourth quarter and full year ended December 31, 2018. Fourth Quarter 2018 Highlights...
Feb 08, 2019 03:47 pm ET
Cambrex to Announce Fourth Quarter and Full Year 2018 Financial Results on February 13, 2019
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that fourth quarter and full year 2018 financial results will be...
Jan 04, 2019 07:35 am ET
New Research Coverage Highlights Twenty-First Century Fox, Hill-Rom, Amphenol, Imperva, Maximus, and Cambrex — Consolidated Revenues, Company Growth, and Expectations for 2019
In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Twenty-First Century Fox, Inc. (NASDAQ:FOX), Hill-Rom Holdings, Inc....
Jan 02, 2019 09:40 am ET
Cambrex Completes Acquisition of Avista Pharma Solutions
Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it has completed the acquisition of Avista Pharma Solutions...
Dec 11, 2018 10:32 am ET
Cambrex Expands Analytical Capabilities at its High Point, NC Site
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it is investing $1 million at its High Point, NC site to fit...
Nov 20, 2018 06:40 am ET
Cambrex to Acquire Avista Pharma Solutions, Adding Early Stage API and Finished Dosage Form Development & Testing Services to its Global Contract Development & Manufacturing Network
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced it has entered into a definitive agreement to acquire Avista...
Nov 08, 2018 06:40 am ET
Cambrex Reports Third Quarter 2018 Financial Results
Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (“APIs”), and finished dosage forms, reports results for the third quarter ended September 30, 2018. Third Quarter...
Nov 05, 2018 03:55 pm ET
Cambrex to Announce Third Quarter 2018 Financial Results on November 8, 2018
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that third quarter 2018 financial results will be released on...
Oct 29, 2018 08:15 am ET
Report: Developing Opportunities within Noah, 3M, Kimberly-Clark, Cambrex, Argan, and Autohome — Future Expectations, Projections Moving into 2018
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Noah Holdings Ltd. (NYSE:NOAH), 3M Company (NYSE:MMM), Kimberly-Clark...
Oct 08, 2018 08:00 am ET
Cambrex Invests c.$3 Million to Upgrade Generic API Manufacturing Facilities at Milan, Italy Site
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms, today announced that it is investing approximately $3 million to increase the...
Oct 08, 2018 07:45 am ET
Market Trends Toward New Normal in Ellington Financial, InfraREIT, Itron, KAR Auction Services, Cambrex, and American States Water — Emerging Consolidated Expectations, Analyst Ratings
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Ellington Financial LLC (NYSE:EFC), InfraREIT, Inc. (NYSE:HIFR), Itron,...
Sep 25, 2018 10:25 am ET
Cambrex to Expand and Invest at High Point, NC Site to Create New Center of Excellence for Process Development and Clinical Supply
Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), and finished dosage forms today announced that it is to establish a center of excellence for API clinical...
Sep 12, 2018 08:45 am ET
Cambrex Completes Acquisition of Halo Pharma
Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced it has completed the acquisition of Halo Pharma (Halo), a leading dosage form Contract...
Aug 29, 2018 08:10 am ET
Cambrex to Present at Upcoming Investor Conferences in September
Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that company management will present at the following investor conferences in September:...
Aug 02, 2018 06:40 am ET
Cambrex Reports Second Quarter 2018 Financial Results
Cambrex Corporation (NYSE: CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the second quarter ended June 30, 2018. Highlights Net...
Jul 27, 2018 11:10 am ET
Cambrex to Announce Second Quarter 2018 Financial Results on August 2, 2018
Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that second quarter 2018 financial results will be released on Thursday, August 2, 2018 before...
Jul 23, 2018 06:40 am ET
Cambrex to Acquire Halo Pharma, Adding Drug Development and Finished Dosage Capabilities to Global API Manufacturing Network
Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced it has entered into a definitive agreement to acquire Halo Pharma (Halo), a leading dosage form...
Jun 20, 2018 08:10 am ET
New Research: Key Drivers of Growth for Winnebago Industries, SkyWest, Brightcove, Selective Insurance Group, Reinsurance Group of America, and Cambrex — Factors of Influence, Major Initiatives and Su
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Winnebago Industries, Inc. (NYSE:WGO), SkyWest, Inc. (NASDAQ:SKYW),...
Jun 12, 2018 08:00 am ET
Cambrex Expands Generic API Research and Development Capabilities at Milan, Italy Site
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it will expand research and development capabilities at its site in Paullo, Milan,...
Jun 01, 2018 09:50 am ET
Cambrex to Present at the Jefferies 2018 Global Healthcare Conference
Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2018...
May 31, 2018 08:00 am ET
Cambrex Invests $5 Million in New Laboratory Expansion at its Karlskoga, Sweden Facility
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it is to commence a $5 million expansion of laboratory facilities at its Karlskoga,...
May 15, 2018 08:00 am ET
Cambrex Completes Pilot Plant Expansion at its High Point, NC Facility
Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed a pilot plant expansion at its High Point, NC facility with the...
May 03, 2018 06:45 am ET
Cambrex Reports First Quarter 2018 Financial Results
Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), reports results for the first quarter ended March 31, 2018. Highlights Net revenue increased 34% to $141.1...
Apr 27, 2018 07:35 am ET
Investor Expectations to Drive Momentum within Blackbaud, Pieris Pharmaceuticals, Sarepta Therapeutics, Cambrex, Stoneridge, and First Interstate BancSystem — Discovering Underlying Factors of Influen
NEW YORK, April 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Blackbaud, Inc. (NASDAQ:BLKB), Pieris Pharmaceuticals, Inc....
Apr 26, 2018 03:15 pm ET
Cambrex to Announce First Quarter 2018 Financial Results on May 3, 2018
EAST RUTHERFORD, N.J., April 26, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2018 financial results will be released on Thursday,...
Apr 23, 2018 08:20 am ET
Cambrex Completes New $3.2 Million Analytical Research & Development Laboratory at its High Point, NC Facility
EAST RUTHERFORD, N.J., April 23, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed the construction and validation of a new...
Apr 19, 2018 04:30 pm ET
Cambrex Corporation to Provide Additional Information Regarding its Environmental, Social and Governance Practices
EAST RUTHERFORD, N.J., April 19, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a commitment to provide its stockholders with additional information regarding its...
Apr 17, 2018 08:00 am ET
Cambrex Invests in New Continuous Flow Technology at its High Point, NC Facility
EAST RUTHERFORD, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed the installation of multiple continuous flow reactor...
Feb 27, 2018 08:20 am ET
Research Report Identifies Insteel Industries, First Cash, Integra LifeSciences, Vishay Precision Group, Cambrex, and Enersys with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
NEW YORK, Feb. 27, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Insteel Industries, Inc. (NASDAQ:IIIN), First Cash,...
Feb 15, 2018 08:00 am ET
Cambrex to Present at the 2018 RBC Capital Markets Global Healthcare Conference
EAST RUTHERFORD, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will participate in...
Feb 08, 2018 06:45 am ET
Cambrex Reports Fourth Quarter and Full Year 2017 Financial Results
- Net Revenue increased 2.5% for the fourth quarter and 9% for the full year 2017-
Feb 08, 2018 06:20 am ET
Cambrex Corporation to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / February 8, 2018 / Cambrex Corporation (NYSE: CBM) will be discussing their earnings results in their Q4 Earnings Call to be held on February 8, 2018 at 8:30 AM Eastern Time.
Feb 02, 2018 09:15 am ET
Cambrex to Announce Fourth Quarter and Full Year 2017 Financial Results on February 8, 2018
EAST RUTHERFORD, N,J., Feb. 02, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that fourth quarter and full year 2017 financial results will be...
Jan 30, 2018 08:00 am ET
Cambrex Expands Process Research and Development Capabilities Across North America
EAST RUTHERFORD, N.J., Jan. 30, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced an investment to expand chemical and analytical development capabilities at its...
Jan 16, 2018 07:00 am ET
Cambrex & AstraZeneca Hold Ceremony to Mark Long-Term Supply Agreement at Karlskoga, Sweden Facility
EAST RUTHERFORD, N.J., Jan. 16, 2018 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today held an opening ceremony with AstraZeneca, at its Karlskoga, Sweden site to...
Dec 20, 2017 08:05 am ET
Analysis: Positioning to Benefit within Cambrex, Enersys, Esterline Technologies, Lsb Industries, Atkore International Group, and Virtusa — Research Highlights Growth, Revenue, and Consolidated Result
NEW YORK, Dec. 20, 2017 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors, traders, and shareholders of Cambrex Corporation (NYSE:CBM), Enersys (NYSE:ENS),...
Nov 08, 2017 08:00 am ET
Cambrex Invests in New Small Scale Capacity at Its Charles City, Iowa Facility
EAST RUTHERFORD, NJ, Nov. 08, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has completed an expansion of cGMP small scale capacity...
Nov 07, 2017 06:45 am ET
Cambrex Reports Third Quarter 2017 Financial Results
- Net Revenue increased 13% and EBITDA increased 29% vs. prior year quarter -...
Nov 07, 2017 06:45 am ET
Cambrex Reports Third Quarter 2017 Financial Results
- Net Revenue increased 13% and EBITDA increased 29% vs. prior year quarter -
Nov 03, 2017 12:00 pm ET
Cambrex to Present at the Stephens Fall Investment Conference
EAST RUTHERFORD, N.J., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at...
Nov 03, 2017 08:00 am ET
Gregory B. Brown M.D. Appointed to the Board of Directors of Cambrex Corporation
EAST RUTHERFORD, N.J., Nov. 03, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Gregory B. Brown, M.D. was appointed to the Company’s Board...
Oct 12, 2017 08:00 am ET
Cambrex Invests in Generic API Development and Manufacturing Capabilities at Its Milan Site
EAST RUTHERFORD, N.J., Oct. 12, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has made a number of investments, in both R&D and manufacturing capabilities to support the development and production of generic APIs, at its site in Paullo, Milan, Italy....
May 31, 2017 02:50 pm ET
Cambrex to Present at the Jefferies 2017 Global Healthcare Conference
EAST RUTHERFORD, N.J., May 31, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2017 Global Healthcare Conference on June 7, 2017 at 2:30 p.m. EDT in New York City....
May 15, 2017 02:00 pm ET
Cambrex to Present at the 2017 UBS Global Healthcare Conference
EAST RUTHERFORD, N.J., May 15, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the 2017 UBS Global Healthcare Conference on May 22, 2017 at 10:30 a.m. EDT in New York City....
May 01, 2017 03:50 pm ET
Cambrex to Announce First Quarter 2017 Financial Results on May 4, 2017
EAST RUTHERFORD, N.J., May 01, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that first quarter 2017 financial results will be released on Thursday, May 4, 2017 before the market opens....
Feb 15, 2017 10:00 am ET
Cambrex to Present at the 2017 RBC Capital Markets Global Healthcare Conference
EAST RUTHERFORD, N.J., Feb. 15, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Steven Klosk, President and Chief Executive Officer, will present at the 2017 RBC Capital Markets Global Healthcare Conference on February 22, 2017 at 8:00 a.m. EST in New York City....
Feb 01, 2017 07:35 am ET
Cambrex to Announce Fourth Quarter and Full Year 2016 Financial Results on February 3, 2017
EAST RUTHERFORD, N.J., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that fourth quarter and full year 2016 financial results will be released on Friday, February 3, 2017 before the market opens....
Nov 04, 2016 07:00 am ET
Cambrex Reports Third Quarter 2016 Financial Results
- Sales increased 8% in the quarter, full year sales and profit guidance increased -...
Nov 01, 2016 01:34 pm ET
Cambrex to Announce Third Quarter 2016 Financial Results on November 4, 2016
EAST RUTHERFORD, N.J., Nov. 01, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that third quarter 2016 financial results will be released on Friday, November 4, 2016 before the market opens....
Oct 31, 2016 06:45 am ET
Bernhard Hampl Appointed to the Board of Directors of Cambrex Corporation
EAST RUTHERFORD, N.J., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that Bernhard Hampl was appointed to the Company’s Board of Directors on October 27, 2016, and will serve on the Board’s Regulatory Affairs Committee.  Dr. Hampl’s appointment increases the size of the Board to ten members....
Oct 03, 2016 03:00 am ET
Cambrex Opens New Pilot Plant at Its Milan, Italy Site
EAST RUTHERFORD, N.J., Oct. 03, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced the validation and ISO certification of a new pilot plant at its state-of-the-art manufacturing and R&D site in Paullo (MI), Italy....
Sep 26, 2016 06:45 am ET
Cambrex to Acquire PharmaCore Inc., to Expand Clinical Stage API Capabilities
EAST RUTHERFORD, N.J., Sept. 26, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), a leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has agreed to acquire PharmaCore Inc., a privately-owned company specializing in developing, manufacturing and scaling up small molecule APIs for clinical phase projects, for approximately $25 million. PharmaCore was founded in 1999 and occupies a 35,000 sq. ft. GMP site in High Point, North Carolina, USA....
Sep 06, 2016 10:00 am ET
Cambrex Announces Investment and Expansion to Large Scale, Multi-Purpose Manufacturing Capabilities at its Karlskoga, Sweden, Facility
EAST RUTHERFORD, N.J., Sept. 06, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced a SEK 72 million ($9 million) investment to expand large scale manufacturing capacity at its Karlskoga facility in Sweden....
Aug 26, 2016 09:40 am ET
Cambrex to Present at Upcoming Investor Conferences in September
EAST RUTHERFORD, N.J., Aug. 26, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE: CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), is pleased to announce that company management will present at the following investor conferences in September:...
Jul 28, 2016 07:00 am ET
Cambrex Reports Second Quarter 2016 Financial Results
- Sales increased 12% for the quarter and full year sales and profit guidance increased -...
Jul 26, 2016 01:07 pm ET
Cambrex to Announce Second Quarter 2016 Financial Results on July 28, 2016
EAST RUTHERFORD, N.J., July 26, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM) announced that second quarter 2016 financial results will be released on Thursday, July 28, 2016 before the market opens....
Jul 12, 2016 09:00 am ET
Cambrex Completes $50 Million Investment in Large Scale API Manufacturing and Storage at Its Charles City, Iowa Site
EAST RUTHERFORD, N.J., July 12, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM), (“Cambrex”), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced the completion and validation of a $50 million state-of-the-art production and warehousing expansion at its cGMP Charles City, Iowa site. The investment in capacity and capabilities was made in reflection of strong market demand for small molecule APIs and high utilization of Cambrex’s existing large scale assets....
Jul 05, 2016 12:45 pm ET
Cambrex to Present at the Cantor Fitzgerald 2nd Annual Healthcare Conference
EAST RUTHERFORD, N.J., July 05, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM) (“Cambrex”) is pleased to announce that Steven Klosk, President and Chief Executive Officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016 at 4:00 p.m. EDT in New York City....
Jun 03, 2016 11:00 am ET
Cambrex to Present at the Jefferies 2016 Global Healthcare Conference
EAST RUTHERFORD, N.J., June 03, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM) (“Cambrex”) is pleased to announce that Steven Klosk, President and Chief Executive Officer, will present at the Jefferies 2016 Global Healthcare Conference on June 10, 2016 at 10:00 a.m. EDT in New York City....
May 23, 2016 06:45 am ET
Cambrex Announces Closing of New $500 Million Senior Credit Facility
EAST RUTHERFORD, N.J., May 23, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM) (“Cambrex”) is pleased to announce that the Company has closed a new $500 million senior secured revolving credit facility (the “Credit Facility”), replacing the previous $250 million facility....
May 16, 2016 10:55 am ET
Cambrex to Present at UBS Global Healthcare Conference
EAST RUTHERFORD, N.J., May 16, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM) (“Cambrex”) is pleased to announce that Steven Klosk, President and Chief Executive Officer, will present at the UBS Global Healthcare Conference on May 23, 2016 at 9:30 a.m. EDT in New York City....
Apr 29, 2016 07:00 am ET
Cambrex Reports First Quarter 2016 Financial Results
- Sales increased 20% and EBITDA increased 52% vs. prior year quarter -...
Apr 27, 2016 10:37 am ET
Cambrex to Present at the Deutsche Bank 41st Annual Health Care Conference
EAST RUTHERFORD, N.J., April 27, 2016 (GLOBE NEWSWIRE) -- Cambrex Corporation (NYSE:CBM) (“Cambrex”) is pleased to announce that Steven Klosk, President and Chief Executive Officer, will present at the Deutsche Bank 41st Annual Health Care Conference on May 4, 2016 at 2:50 p.m. EDT in Boston, MA....